Patient Brochure on Breast Cancer Tumor Markers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

MALVERN, Penn-Centocor, Inc., a manufacturer of cancer diagnostics, including the CA 15-3 radioimmunoassay serum tumor marker for breast cancer monitoring, has produced a brochure for patients on the early detection of breast cancer recurrence. The pamphlet reviews the need for regular physical exams and laboratory testing, the signs and symptoms to look for between exams, and the role of tumor marker assays in monitoring. The brochure is free to health care providers, cancer organizations, and the public. Write to Breast Cancer Tumor Markers and Follow-up Care, PO Box 1883, Southeastern, PA 19399-1883.

MALVERN, Penn—Centocor, Inc., a manufacturer of cancer diagnostics, including the CA 15-3 radioimmunoassay serum tumor marker for breast cancer monitoring, has produced a brochure for patients on the early detection of breast cancer recurrence. The pamphlet reviews the need for regular physical exams and laboratory testing, the signs and symptoms to look for between exams, and the role of tumor marker assays in monitoring. The brochure is free to health care providers, cancer organizations, and the public. Write to Breast Cancer Tumor Markers and Follow-up Care, PO Box 1883, Southeastern, PA 19399-1883.

Articles in this issue
Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
3 experts in this video
Related Content
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

Lee Schwartzberg, MD, FACP;Omkar Marathe;Shanta Chawla;Jeffrey L. Vacirca;Kenneth Crist;Howard Franklin;Manuel Modiano
April 23rd 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen
April 21st 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Roman Fabbricatore
April 21st 2025
Article

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

Zeynep Ozlem Soran;Allison Brophy;Lily Kass;Berkay Demirors;Hayeon Kim;Atilla Soran, MD, MPH;John Austin Vargo;Parul Barry
April 20th 2025
Article